Chinese regulators have removed the lid on an estimated CNY8bn ($1.3bn) domestic market to COVID-19 vaccine makers with the first approvals for heterologous booster jabs. Companies are now rushing to develop their candidates and inoculate potentially hundreds of millions of people.
Two producers, Shanghai- and Hong Kong-listed CanSino Biologics Inc. and Shenzhen-listed Chongqing Zhifei Biological Products Co. Ltd., obtained...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

